E-mail this page: News Release
FDA Approves KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy
To (e-mail address):
Separate multiple addresses with commas. Maximum 200 characters.
Your e-mail address:
These e-mail addresses will be used to e-mail the page on your behalf and will not be used by Savient Pharmaceuticals for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps Savient Pharmaceuticals prevent automated submissions.